INTRODUCTION
Muscle wasting is prominent in many pathologies including metabolic disorders and neuromuscular diseases. Muscle wasting is also associated with aging and is highly prevalent in the elderly (Bowen et al., 2015) . The molecular and cellular causes for aging-associated muscle wasting are diverse. Recently, we reported that muscle wasting is induced by reduced levels of poly(A)-binding protein nuclear 1 (PABPN1) . PABPN1 levels are normally reduced in skeletal muscles during aging and are also associated with muscle weakness in oculopharyngeal muscular dystrophy (OPMD), a late-onset myopathy . An expansion mutation in PABPN1 is the genetic cause for OPMD (Brais et al., 1998) . In OPMD, PABPN1 aggregates and hence depletes the levels of the functional protein (Raz et al., 2011) . PABPN1 regulates poly(A) tail length, alternative polyadenylation (APA) in the 3 0 UTR or in internal regions, and nuclear export of transcripts, which together will affect mRNA expression levels, leading to an altered transcriptome (Banerjee et al., 2013) . The mechanisms by which PABPN1 depletion leads to muscle wasting are not fully understood.
Muscle wasting in OPMD mouse models is associated with the ubiquitin proteasome system (UPS) (Anvar et al., 2011a (Anvar et al., , 2011b Trollet et al., 2010) . Also, in the mouse muscles with PABPN1 knockdown (shPab) muscle atrophy was found to be associated with altered mRNA levels of UPS genes that regulate muscle atrophy . Reduced proteasomal activity in shPab muscles suggests that protein homeostasis is altered in shPab muscles. Protein homeostasis plays a central role in aging-associated muscle wasting (Cohen et al., 2014) . Muscle contraction demands mitochondrial activity, and unsurprisingly altered mitochondrial activity was found in OPMD models, which was concomitant with shortened poly(A) tail length and APA in the 3 0 UTR of mitochondrial genes (Chartier et al., 2015; Vest et al., 2017) . Yet, how altered mRNA expression profiles lead to muscle wasting remains obscure.
Here we applied RNA sequencing (RNA-seq) and mass spectrometry in shPab muscles to identify the molecular and cellular causes for muscle wasting. We show that protein acetylation is reduced in shPab muscles and that deacetylation inhibition restores PABPN1-mediated muscle wasting.
RESULTS

PABPN1 Down-regulation Alters Muscle Histology
We investigated the molecular mechanisms that are associated with PABPN1-driven muscle wasting in mouse tibialis anterior muscles expressing short hairpin RNA (shRNA) to Pabpn1 (shPab). PABPN1 levels in muscles from four mice were compared between shPab and scrambled shRNA (scram) after contralateral injection, as previously described . In this experimental setup analysis was paired, overcoming natural variations between mice. Muscles were harvested for ex vivo procedures including RNAseq and mass spectrometry, and validations were carried out using qRT-PCR, western blot, and muscle histology ( Figure 1A) . Transduction efficiency was assessed by GFP fluorescence, which was included in the expression cassette. Overall, similar fluorescence was found in shPab and scram muscles ( Figure S1 ), indicating that any alterations in PABPN1 levels are not due to variation in transduction efficiency. Analysis of PABPN1 demonstrated reduced levels in shPab muscles (Figures 1B and 1C) . Muscle histology was found to be altered between scram and shPab ( Figure 1D ). We confirmed thickening of the extracellular matrix (ECM) in shPab muscles ( Figure 1D ; . We also measured more myofibers per image frame in shPab compared with scram muscles ( Figure 1E ). Smaller myofibers could result from muscle atrophy, which is consistent with our previous study ; furthermore, it can concur with muscle regeneration. Central myonuclei and split myofibers were found in shPab muscles ( Figure 1D ). The fraction of central myonuclei in shPab was higher in three of the four mice ( Figure 1F ). PAX7 and eMyh3 expression are molecular signatures of muscle regeneration (Lepper et al., 2011; Sambasivan et al., 2011; Schiaffino et al., 2015) . qRT-PCR of eMyh3 mRNA revealed higher levels in shPab muscles ( Figure 1G ). PAX7 staining also showed the same trend, wherein the fraction of PAX7-positive myonuclei was higher in shPab muscles (Figures 1H and 1I) . Noticeably, the mouse with the highest PABPN1 fold change showed the most severe histological changes, whereas the mouse with the lowest fold change showed resilient changes.
Proteomic Changes Surpass the Transcriptomic Changes in shPab Muscles
The molecular mechanisms that are associated with PABPN1-mediated muscle pathology were investigated in the shPab transcriptome and proteome from the same muscles, using paired ratio t test. The shPab RNA expression profiles included 363 genes (5% false discovery rate [FDR]; Figure 2A , related to Table S1 ), and those were predominantly enriched with genes of the ECM, mitochondria, and musclerelated genes (related to Table S2 ). These expression profiles are consistent with OPMD expression profiles (Anvar et al., 2011a; Raz et al., 2013) . Moreover, higher expression of ECM genes is consistent with ECM thickening in shPab muscles . qRT-PCR validation was carried out for Pabpn1 and eMyh3 (Figures 1 and 2A ). For the proteome, a 5% FDR cutoff was too strict (Related to Table S3 ). Considering a p value cutoff of p < 0.05, we identified differential expression of additional genes, such as Rad32a and Map1lc3a, which were previously reported as differentially expressed in shPab (Raz et al., 2017; . The shPab proteome contained 248 differentially expressed proteins (p < 0.05) ( Figure 2B , related to Table S3 ). Western blot for seven proteins validated the proteomics results ( Figure S2) . A significant correlation (p = 2.2 3 10 À16 ) was found between mRNA and protein fold changes. The regression line is similar to the diagonal, although the correlation was small (R = 0.31) ( Figure 2C ). Overall, protein fold change was greater compared with mRNA fold change ( Figure S3 ). Focusing on the group of genes or proteins with higher fold changes (average fold change > j1.5j) we found that the majority of the proteins had a positive fold change in shPab muscles (68%, Figure 2D ). In contrast, a fold change direction preference was not found for the mRNAs ( Figure 2D ). The same fold change direction between mRNA and proteins was found for nearly 70% of the proteins, of which most proteins (74%) have higher levels in shPab ( Figure 2E ). In the group with opposite fold change direction between mRNA and protein (30%), the majority of proteins (80%) had higher levels in shPab ( Figure 2E ). Together, this suggests that in shPab muscles protein accumulation surpasses mRNA alterations. Moreover, protein accumulation in shPab suggests higher protein steady state, which is in agreement with reduced proteasome activity in shPab .
A heatmap of the differential expressed proteins (p < 0.05, N = 248 proteins) across the four individual mice revealed that the largest differences between scram and shPab muscles were found in the mouse with the highest PABPN1 fold change, whereas in the mouse with the lowest PABPN1 fold change the differences were the smallest ( Figure 3A ). This trend was then confirmed using k-means clustering. For 83 proteins, fold changes highly correlated with PABPN1 levels ( Figure S4 ). Validation using western blot was demonstrated Continued (H and I) (H) Representative fluorescent images for scram and shPab muscles stained with PAX7 antibody (green). Nuclei are counterstained with DAPI (blue). White arrowheads indicate nuclear PAX7. Scale bar, 7.5mm. (I) Paired dot plot shows the fraction of PAX7 positive nuclei in paired muscles. The percentage was calculated from over 1,000 nuclei per muscle (N = 6 muscles). In all dot plots paired muscles are connected with lines; blue or green lines mark the mouse with the highest or lowest PABPN1 fold change, respectively. Quantification of the muscle histology was performed over the entire muscle cross section. Means and standard deviations are depicted. Statistical difference was assessed with a paired test.
for two proteins ( Figure S2 ). Together, these results suggest that the levels of a subset of proteins strongly correlate with the PABPN1 fold change.
The cellular machineries that are affected by PABPN1 were then identified in the shPab proteome using enrichment analysis. The mitochondria, ribosome, cytoskeleton, nucleotide binding, glycolysis, and muscle (C) Scatterplot shows the fold changes between shPab proteome and transcriptome. Correlation (indicated as gray dashed line) was assessed with a Spearman rank test and compared with the diagonal (solid gray line). Average protein fold changes of 1.5 and À1.5 are indicated with red lines. Proteins with an average fold changes higher than 1.5 or lower than À1.5 are depicted in pink or black, respectively. (D) Bar chart shows fold change direction of shPab-affected genes (average fold change cutoff > j1.5j) sorted for RNA or proteins.
(E) Bar chart shows the percentage of proteins (average fold change cutoff > j1.5j) with similar fold change direction or opposite fold change direction compared with RNA direction. Fold change higher than 1.5 is denoted in black and fold change lower than À1.5 in pink. Both transcriptome and proteome were determined from the same muscles (N = 4 mice).
proteins were found to be the most prominently affected ( Figure 3B ). Notably, mitochondrial proteins had lower levels, whereas most of the ribosomal proteins had higher levels in shPab muscles ( Figure 3A ). Next, protein-protein interaction networks of the differentially expressed proteins revealed that networks of the mitochondria, translation, cytoskeleton, and glycolysis were the most connected ( Figure 3C ). This suggests (C) The protein-protein interaction map shows protein networks for 248 proteins that pass the cutoff (p < 0.05). Mitochondrial (green), translation (red), cytoskeletal (purple), and glycolysis (pink) clusters are highlighted. Within the mitochondrial cluster, the oxidative phosphorylation group is highlighted in dark green. Unconnected proteins are not shown, and networks with n < 4 are removed. Proteins that are found in the acetylation group are highlighted in yellow, and those that were not found in the acetylation group are gray. Figure 4 . The shPab-Dependent Acetylome (A) A workflow of the shPab acetylome procedure. Tibialis anterior muscles (N = 7 mice, contralateral injection of scram or shPab AAVs) were used. Protein extracts were pooled per genotype. Tryptic digestion, followed by immunoprecipitation with an anti-acetylated lysine (AcK) antibody, and mass spectrometry (MS) were carried out separately for the scram and shPab. Peptide analysis pipeline included an MS quality control (1% FDR) and coefficient of variation (CV) < 0.3. The differentially acetylated peptides were considered with a 1.5-fold change (fold change) cutoff.
iScience 12, 318-332, February 22, 2019 323 that the function of these cellular machineries is impaired in shPab muscles. Most striking, 63% of the proteins in the shPab proteome were enriched in the acetylation group (related to Table S4 ). Most mitochondrial proteins in the shPab proteome were also found in the acetylation group ( Figures 3B and 3C ). Moreover, acetylation was also found to be abundant in the other enriched cellular machineries ( Figures  3B and 3C ), suggesting that acetylation might have a prominent role in shPab muscles.
shPab Muscles Are Characterized by Reduced Protein Acetylation
To elucidate the acetylated protein landscape in shPab muscles, a peptide pull-down with an antibody to acetylate lysine was carried out in scram and shPab muscles. For this purpose, protein extracts from seven mice, which were injected contralaterally with scram or shPab adeno-associated virus (AAV) 9 particles, were pooled and the pull-down peptides were identified using mass spectrometry ( Figure 4A ). In total, 2,229 peptides passed the 1% FDR and overlapped between two independent runs (related to Table  S5 ). A total of 1,830 peptides (82%) passed the coefficient of variation cutoff and were considered for subsequent analysis ( Figure 4B ). A confidence in the identified acetylated peptides was further assessed comparing our study in tibialis anterior muscles with the following published acetylome studies: in human and in rat skeletal muscles (Lundby et al., 2012) and in rat soleus (Ryder et al., 2015) . Only $13% of the acetylated peptides overlapped between the human and rodent acetylomes (related to Table S6A ). As the human and rat studies came from the same laboratory and have a similar number of acetylated peptides (Lundby et al., 2012) , it can be assumed that the limited overlap is not due to experimental settings or technical variations. The overlap between the two studies in rat was only 35% and comparable to the overlap between our study and the study in rat by Lundby et al. The specific muscle type was not specified in the study by Lundby et al. However, peptide overlap between fast-twitch tibialis anterior and slow-twitch soleus was only 13% (200 peptides; related to Table S6B ). In the pool of the overlapping peptides between soleus and tibialis anterior the mitochondria was highly enriched (Table S6C) , which is consistent with mitochondria enrichment in the acetylome studies in rat and humans (Lundby et al., 2012) . Using western blot, we confirmed that the pattern of bulk protein acetylation highly differs between soleus and fast-twitch quadriceps in mouse ( Figure S5 ). Differences in histone acetylation were reported between fast and slow muscles (Kawano et al., 2015) . Moreover, 82% of those overlapping acetylated proteins are also annotated in DAVID as acetylated proteins (related to Table S6C ). Together, this suggests that in skeletal muscles the acetylated mitochondrial proteins are highly abundant. Furthermore, it indicates that our acetylome study is suitable for further analysis. We then investigated differential peptide acetylation between scram and shPab muscles and considered a fold change of 1.5 as a cutoff. In the shPab acetylome, 270 peptides were hypoacetylated and 137 peptides were hyperacetylated ( Figure 4B ). We found that 87 and 61 acetylated peptides were exclusively found in scram and shPab muscles, respectively ( Figure 4B ). This suggests an overall reduced acetylation in shPab muscles. Differences in protein acetylation between scram and shPab muscles were confirmed using western blot ( Figure 4C ). In addition, immunofluorescence also showed a decrease in the acetylation signal in shPab nuclei compared with scram muscles (Figures 4D and 4E) . To confirm this observation, acetylation direction was assessed for nuclear proteins in the shPab acetylome. Hypoacetylation was also prominent in the nuclear proteins, including all histones ( Figure 4F ). Moreover, enrichment analysis of the differentially acetylated proteins (N = 171) showed that the mitochondria was highly enriched ( Figure 4G ). In addition, 42% of the differentially acetylated proteins were enriched in metabolic pathways ( Figure 4G ). The majority of the differentially acetylated oxidative phosphorylation proteins were found to be in complexes 1 and 5 ( Figure 4H ). These complexes catalyze, respectively, the production of NAD + and ATP (Lenaz et al., 2006) . This could suggest aberrant mitochondrial activity in shPab muscles. In agreement, previously we reported reduced mitochondrial membrane potential in shPab muscle cell culture . Acetylation of mitochondrial proteins is achieved by the NAD + -dependent deacetylases (sirtuins), among which SIRT1 is suggested to be central in aging-associated metabolic changes in muscles (Chang and Guarente, 2014) .
PABPN1 Regulates SIRT1 mRNA Processing
We then examined SIRT1 levels in shPab muscles and found an elevated protein expression in shPab compared with scram muscles (Figures 5A and 5B ). Interestingly, SIRT1 fold changes related to PABPN1 fold changes ( Figure 5B ). Therefore next we investigated whether SIRT1 is regulated by PABPN1 in an established PABPN1 knockdown muscle cell culture . SIRT1 protein levels were also elevated in shPab cell culture ( Figure 5C ). Thus we examined whether Sirt1 transcript level is directly regulated by PABPN1. APA was determined with the ratio between two primer sets to distal and proximal region in Sirt1 3 0 UTR ( Figure 5D ). We found a lower distal to proximal ratio in shPab cell culture ( Figure 5E ), indicating APA utilization. APA often resulted in shorter transcripts that are more stable Jenal et al., 2012) . Using the proximal primer set we found higher Sirt1 mRNA levels in shPab cell culture (Figure 5F) . Consistently, also in the OPMD mouse model (A17.1) we found APA and higher levels in Sirt1 mRNA ( Figure S6 ). Interestingly, APA and higher Sirt1 expression were only found in fast-twitch quadriceps, but not in slow-twitch soleus ( Figure S6 ). In this mouse model, soleus is also less affected (Trollet et al., 2010) .
Next, we investigated whether Sirt1 mRNA is directly regulated by APA utilization. We designed antisense oligonucleotides (AONs) specific to the proximal polyadenylation signal (PAS) in Sirt1 3 0 UTR or scrambled AON ( Figure 5G ; Related to Table S7 ). The AONs were transfected into cell cultures, and masking of proximal PAS was assessed using the distal to proximal ratio. Compared with scrambled AON, the distal to proximal ratio was higher in Sirt1-AONs in shPab cell culture ( Figure 5H ), and consistently, Sirt1 long transcript levels were also elevated ( Figure 5I ). Together this suggests that in conditions with reduced PABPN1 levels Sirt1 levels are modulated via APA utilization. In control cells, Sirt1 mRNA was also elevated after Sirt1-AON transfection, which was not due to APA utilization ( Figures 5H and 5I ), suggesting that additional factors affect the stability of long Sirt1 transcript.
SIRT1 Inhibition Elevates PABPN1 Expression in shPab Cell Culture
Next, we investigated whether SIRT1 inhibition could reverse mitochondrial activity in shPab cell culture. Treatment with sirtinol, a SIRT1 inhibitor (Villalba and Alcaín, 2012) , caused an increase in mitochondrial membrane potential in shPab cell culture ( Figure 6A ). Also, in shPab cell cultures that were treated with Sirt1-AON we found an increase in mitochondrial membrane potential ( Figure S7 ). In addition, sirtinol treatment restored muscle cell fusion in shPab cell culture ( Figure 6B) . Consistently, increased cell fusion was also found in stable SIRT1 knockdown cell culture ( Figure S8 ). This suggests that inhibition of SIRT1 activity restores PABPN1-mediated myogenic defects.
We then explored if SIRT1 inhibition affects PABPN1 function. We found that PABPN1 protein levels were elevated in a dose-dependent manner with 10 mM as the optimal sirtinol concentration ( Figure S9 ). Consistently, PABPN1 increased in scram and shPab cells treated with sirtinol ( Figure 6C ). Consistently, PABPN1 levels were also increased in SIRT1 knockdown muscle cell culture ( Figure S8 ). Sirtinol treatment also elevated the levels of nuclear PABPN1 in shPab cell culture ( Figure 6D ). As nuclear PAPBN1 regulates APA utilization, we determined the distal to proximal ratio of Sirt1 mRNA in sirtinol-treated cells, and found a reversion compared with shPab cell culture ( Figure 6E ). Consistently, Sirt1 fold change was also reduced ( Figure 6F ). In a recent study we showed that PABPN1 also regulates levels of several autophagy-related genes (Raz et al., 2017) . Sirtinol treatment also restored levels of four of five autophagy-related genes (Figure 6F) . Together, the results suggest that sirtinol treatment restores PABPN1 levels and its activity. Hence, this treatment could be beneficial in conditions with reduced PABPN1 levels.
Sirtinol Treatment Restores PABPN1-Mediated Muscle Wasting
We then investigated the effect of sirtinol treatment in shPab muscles. Sirtinol or empty vehicle was contralaterally injected into shPab muscles of three mice ( Figure 7A ). Treatment was repeated twice, and iScience 12, 318-332, February 22, 2019 325 muscles were harvested for ex vivo analyses ( Figure 7A ). Same as in cell culture, PABPN1 protein levels were increased in sirtinol-treated muscles (Figures 7B and 7C ). In the sirtinol-treated shPab muscles ECM thickening was reduced and split myofibers were absent ( Figure 7D ). In addition, we observed a strong trend wherein the percentage of central nuclei decreased in sirtinol-treated muscles and myofiber crosssectional area increased ( Figures 7E and 7F) . Previously we reported a shift in myofiber typing in shPab muscles: myosin-heavy chain (MyHC)-2b reduced, but MyHC-2a slightly increased . Sirtinol treatment restored myofiber typing: MyHC-2b was elevated and MyHC-2a was reduced ( Figure 7G) . Last, we also noticed that MyHC-2b foci were formed in shPab muscles, which were completely absent in scram muscles ( Figure S10 ). This was consistent with our previous study . MyHC-2b foci are formed by the loss of ACTN3 (MacArthur et al., 2007) . In agreement, reduced ACTN3 protein levels were found in the shPab proteome (related to Table S3 ). The number and size of MyHC-2b foci were decreased in sirtinol-treated shPab muscles ( Figure 7H ). Taken together, this suggests that sirtinol treatment could be beneficial in PABPN1-mediated muscle wasting.
DISCUSSION
Muscle wasting is characterized by multiple histological alterations such as, atrophy, regeneration, thickening of the ECM, and switches in myofiber typing. Dysregulation of pathways regulating protein homeostasis, like the UPS and autophagy, play a role in muscle atrophy (Schiaffino et al., 2013) . Reduced PABPN1 levels regulate expression levels of UPS, autophagy, and mitochondrial genes via APA utilization in the 3 0 UTR, which consequently lead to reduced activity of all the cellular machineries (Chartier et al., 2015; Raz et al., 2017; . Reduced PABPN1 levels cause myogenic defects in muscle cell culture Apponi et al., 2010) . Moreover, muscle wasting is found in mouse models for OPMD (Trollet et al., 2010; Vest et al., 2017) . ECM thickening and central nuclei were also reported in affected OPMD muscles . Also, in shPab muscles we found ECM thickening and central nuclei, suggesting that reduced PABPN1 levels cause multiple pathological features of muscle wasting and myogenic defects. PABPN1 regulates mRNA processing, yet it is not fully understood how an altered transcriptome leads to muscle wasting pathology. Recently we showed that transcripts from APA in the 3 0 UTR are under-represented in the translation machinery (Raz et al., 2017) . Substantial discrepancies between mRNA fold changes and translation efficiency were also reported in muscle cell cultures (de Klerk et al., 2015) . Here we found only limited correlation between transcript and protein fold changes in the same muscles. In agreement, limited overlap between transcriptome and proteome was also reported in muscles from aged adults (Robinson et al., 2017) . Limited correlation between outcomes from RNA-seq-based transcriptome and mass-spectrometry-based proteome could be affected by technical issues and in-depth differences. Noteworthy is that for the more affected genes (fold change j>1.5j), variation of their corresponding proteins is generally of a greater magnitude. This suggests that despite a genome-wide effect of PABPN1 on mRNA processing, only a subset of transcripts affect the muscle pathology. Higher protein fold changes in shPab muscles are consistent with lower proteasome activity and reduced autophagosome formation (Raz et al., 2017; . Posttranscriptional drivers of muscle wasting are associated with protein breakdown regulated by the ubiquitin proteasome and autophagy lysosome pathways (Schiaffino et al., 2013) . Also, in aging muscles and in OPMD models, dysregulation of protein homeostasis seems to play a central role (Anvar et al., 2011b; Murgia et al., 2017; Raz et al., 2013; Vest et al., 2017) . A broader effect on protein catabolism is implicated by higher levels of the ribosomal proteins in aging muscles, shPab muscles, and OPMD models (Murgia et al., 2017; Robinson et al., 2017; Vest et al., 2017) . In addition, reduced expression of mitochondrial proteins is also commonly found in shPab, OPMD, and aged muscles (Murgia et al., 2017; Robinson et al., 2017; Vest et al., 2017) . In OPMD muscles, reduced mitochondrial activity is correlated with APA utilization in a subset of mitochondrial genes (Chartier et al., 2015) . Mitochondrial activity is more robustly regulated by reversible acetylation (Baeza et al., 2016) . Acetylation of mitochondrial proteins is common in skeletal muscles (Lundby et al., 2012) . Differential acetylation of mitochondrial proteins was found to be prominent in atrophic rat muscles (Ryder et al., 2015) , and consistently also in shPab muscles, with complexes I and V being the most affected. NAD + production is carried out in complex I, and sirtuins activity is NAD + dependent. We show that deacetylation inhibition by sirtinol treatment in shPab restored mitochondrial membrane potential and myogenic defects.
Acetylation affects protein levels and function, among which the effect on metabolic processes is widely studied (Drazic et al., 2016) . Acetylation is regulated by the sirtuins NAD + -dependent deacetylase gene family (Imai and Guarente, 2016) . SIRT1 facilitates metabolic benefits in various cells across different tissues, and a central role in aging muscles was elucidated in many studies (Chang and Guarente, 2014) . The mechanisms regulating SIRT1 levels in aging tissues are inadequately understood. Here we show that SIRT1 levels are directly tuned by PABPN1 via APA in the 3 0 UTR. Masking the proximal polyadenylation site using specific AONs restored APA in SIRT1 and mitochondrial membrane potential in shPab muscle cell culture. Masking APA using oligonucleotides to pathogenic molecules was suggested as a specific silencing approach (Chen et al., 2016; Marsollier et al., 2016; Raz et al., 2014) . Moreover, SIRT1 inhibition restored PABPN1 levels, PABPN1 function, and myogenesis defects, suggesting that SIRT1, directly or indirectly, regulates PABPN1 levels. Acetylated PABPN1 was identified in the SIRT1-dependent acetylome (Scholz et al., 2015) , suggesting that PABPN1 could be modulated by SIRT1-dependent deacetylation. Yet, how acetylation of PABPN1 affects its level and function should be explored in future studies. Nevertheless, we show that acetylation inhibition restored muscle wasting in shPab. Our results are consistent with studies suggesting that restoring NAD + levels or targeting SIRT1 could ameliorate the age-associated disorders (Giblin et al., 2014; Villalba and Alcaín, 2012) (Tarragó et al., 2018) . Moreover, sirtinol has been shown to reduce aggregation of the expanded PABPN1 in a C. elegans model for OPMD (Catoire et al., 2008; Pasco et al., 2010) . In prokaryotes, increased acetylation leads to enhanced aggregation and formation of inclusion bodies (Kuczynska-Wisnik et al., 2016) . Whether deacetylation directly affects protein aggregation in muscles needs to be investigated in future studies.
Taken together, we show that muscle wasting, atrophy, and regeneration are induced by reduced PABPN1 levels. The shPab proteome shows a modulated protein acetylation profile, and the shPab acetylome is predominantly hypoacetylated. Reduced protein acetylation is consistent with higher SIRT1 levels. We show that Sirt1 mRNA is regulated by PABPN1, and in turn, SIRT1 inhibition or knockdown elevates PABPN1 protein levels and restores PABPN1 molecular function. Consequently, cellular defects and muscle wasting are repaired in conditions with reduced PABPN1 levels. Our study suggests that maintaining physiological levels of both PABPN1 and SIRT1 is beneficial for muscles, and disturbance causes muscle wasting. This is the first study showing that reduced PABPN1 levels broadly affect protein acetylation. Future studies in other models and possibly in human aging muscles will further validate the role of PABPN1 in the protein acetylation landscape and its effect on muscle wasting.
Limitations of the Study
This study presents the role of protein deacetylation in a mouse model, which was generated by AAV9expressing shRNA to PABPN1. Our study design allowed paired analysis, excluding inter-mice variations. Yet, parts of this study should be replicated in other models. Recently, two other mouse models for PABPN1 were published (Vest et al., 2017) , and these should be considered in future studies. The role of protein deacetylation in aging muscles should be further studied in human muscles.
METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.
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Deacetylation Inhibition Reverses Tables   Table S1. The shPab Transcriptome. Related to Fig. 2A Table S2. Gene enrichment in shPab transcriptome. Related to Fig. 2A A top list of the six most significant enriched gene ontology of the candidate with altered mRNA expression levels in shPab muscles (p<0.05, FDR). Highlighted in bold are the terms that are shown in the pie-chart ( Figure 3B ). A. Western blot validation for seven proteins from the mass spectrometer. CSRP3, UCH-L1, MURC and OTUB1 were confirmed to be changing in the shPab proteome. WB of UCH-L3, UBE2N and GAPDH confirmed no change in their expression as detected by the mass spectrometer. Paired muscles are indicated. The mouse with the highest PABPN1 FC is depicted in blue and the lowest PABPN1 FC in green. B. Protein expression levels were normalized to GAPDH and the average of all scram muscles. Paired analysis was carried out in N=4 mice. Statistical difference was determined with the paired t-test. p<0.05 in marked (*). Normalized protein abundances plotted for 83 proteins that clustered according to PABPN1 fold change across N=4 mice. Values in technical replicates (N=2) in scram and shPab are shown for every muscle. Paired muscles are connected. The mouse with highest or lowest PABPN1 fold change is depicted in blue or green, respectively. Amongst the 83 proteins, ribosomal proteins were highly present (~25%) as well as cytoskeletal proteins (~18%). Two proteins, CSRP3 and UCH-L1 were validated using western blot (Fig. S2) . Related to Fig. 7 .
PABPN1-Dependent Muscle Wasting
Group term
Representative images of MyHC-2B staining in scram and shPab muscle cross-section. shPab muscles clearly show formation of MyHC-2B foci whereas these were completely absent in scram muscles. Scale bar is 50 µm. Density plot shows the acetylome distribution before (left) and after normalization (right). Black line indicates scram and blue the shPab samples.
Transparent Methods
Animal ethics Statement
Animal experiments were conducted according the animal research protocol (DEC # 13113) approved by the animal ethical committee, LUMC, Leiden, the Netherlands, and all experiments were carried out in accordance with the ARRIVE guidelines as previously described .
Mouse strain, AAV injection and live mice imaging PABPN1 was down regulated in mice muscles as previously described . In brief, four mice were injected with AAV-based expression cassette containing shRNA to Pabpn1 and scrambled shRNA (Table S7 ). AAV9 particles (1.5 x 10 12 gc in 50 µl PBS) of Pabpn1 (shPab) or scrambled (scram) shRNA were contralaterally injected into left or right leg muscles, tibialis anterior. AAV injections, mice house-keeping and muscle harvesting were carried out as detailed in , with the exception that in this study muscles were harvested five weeks post-injection for the proteome and transcriptome studies and three weeks post-injection for the acetylome study.
For sirtinol treatment, the aforementioned AAV9-shPab particle dosage was injected into tibialis anterior muscles of both left and right leg of three mice (N=3). AAV9-Scrambled particles were injected into three additional mice as control. Three weeks post AAV injection, the left leg tibialis anterior muscle was injected with sirtinol (0.014 µg/ g muscle mass), and the right leg tibialis anterior muscle was injected with PBS/DMSO (1:1000) vehicle as a control. A second dosage of sirtinol or vehicle was injected after 10 days, and mice were sacrificed after the sixth week of AAV9 injection.
Muscles were harvested and stored as described above for subsequent ex-vivo analyses.
Muscle cell culture
Stable knockdowns were generated in immortalized mouse myoblasts C2C12 were generated using a lentivirus transduction containing shRNA to Pabpn1 as previously described or shRNA to Sirt1 (Table S7 ). Cells were maintained in growth medium (DMEM+10% FCS) containing puromycin (2.5 µg/mL; Sigma-Aldrich). Cell fusion was conducted in DMEM+2% horse-serum for 10 days. Sirtinol (10µM, Sigma Aldrich) treatment was carried out for 24 hours. AONs to SIRT1 (Table S7) were transfected (1µg) using PEI reagent (Sigma). Scrambled AON FITCconjugated was used to assess transfection efficiency as described in (Aartsma-Rus et al., 2004) . mRNA levels and mitochondrial activity were determined 48 hours post-transfection.
RNA procedures RNA isolation, library preparation and sequencing RNAseq analysis
Total RNA from scram and shPab muscles of all four mice was isolated using Qiagen miRNeasy Mini kit (Qiagen BV, Venlo, The Netherlands), as described in . The quality of bulk RNA including small RNA was determined using bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). cDNA library for RNAseq was prepared from 500ng RNA using oligo-dT Dynabeads (LifeTech 61002) (Parkhomchuk et al., 2009 ). The NEB Next generation sequencing kit was used to prepare the samples for strand-specific sequencing without a size selection step, according to the manufacturer instructions with following modifications: the library was treated with USER enzyme (NEB M5505L, New England BioLabs Inc, Ipswich, MA, USA) to digest fragments derived from the second strand. After amplification of the libraries, samples with unique sample indexes were pooled and subjected to paired-end 2x100 base pair sequencing on one Illumina-HiSeq2000-v3 lane as per manufacturer instructions (Illumina HQ San Diego CA, USA). Analyses and base calling were carried out by the Illumina pipeline (Illumina HQ San Diego CA, USA). The paired end raw reads were aligned to the GRCm38/mm10 mouse reference genome using the GENTRAP (Generic Transcriptome Analysis Pipeline, March 2015, developed by SASC, https://git.lumc.nl/rig-framework/gentrap) pipeline. Strand specific alignment was carried out with GSNAP version 2013-10-12 using default settings except for novel splicing (=1). UCSC Ensembl transcripts (downloaded on July 17, 2014) were used to identify coding regions (CDS) annotations. Cufflinks v.2.1.1 strict mode was used for quantification of reads at gene and transcript levels. RNAseq QC features are found in Table S8 . Normalization was carried out using the trimmed mean of M values (TMM) (Robinson and Oshlack, 2010) . The effect of TMM normalization on reads' distribution is shown in Fig. S11 . Raw counts were normalized in EdgeR version 3.14.0 using TMM, and differential expression was determined after fitting a generalized linear model with two fixed effects, donor (mouse) and type (muscle type), using the glmFit function and using tag-wise dispersion estimates. Low quality reads and adaptor sequences (<1%) were filtered out. On average over 10 million reads per sample were mapped to gene exon regions and were counted in further analysis. We did not find significant differences in quality control sequencing features between scram and shPab muscle samples (Table S8 and Fig. S11 ). Differential expression was identified with the DiffExpr2, an in-house developed pipeline, using a paired log-ratio likelihood (LRT) on gene level. Quantitative RT-PCR Total RNA was isolated from cell cultures using Nucleospin kit, Macherey-Nagel. Complementary DNA synthesis was carried out using the RevertAid First Strand cDNA Synthesis Kit (Thermo Fisher Scientific). 3 ng cDNA was used as template per PCR reaction with specific primers (Table S9 ). qRT-PCR was carried out using LightCycler 480 System (Roche Diagnostics). All qRT-PCR from cell culture were run in biological triplicates and technical duplicates. The qRT-PCR runs from the muscles of all four mice have been done in technical triplicates. Expression levels were calculated after normalization to Hprt housekeeping gene. A change in PAS utilization was calculated by the ratio of PCR products between distal to proximal primer sets.
Protein procedures Protein extraction from muscles
To minimize biological variations, parts of the same muscles that were used for histology and RNA analyses were used for protein analysis. 20 mg muscle tissue from scram and shPab muscles of all four mice was homogenized in RIPA extraction buffer (50mM Tris, pH 7.4, 150mM NaCl, 1% SDS, 0.5% sodium deoxycholate, 1% Igepal CA-630 and protease inhibitors cocktail (Sigma-Aldrich) with plastic beads using bead beater (Precellys Stretton Scientific). The muscle extract was subsequently sonicated on ice (3x 5 seconds, 15W). Protein concentrations were determined with a BCA protein assay kit (Pierce, Thermo Fisher Scientific). For the acetylome, proteins were extracted using 9M urea buffer (20mM HEPES pH 8.0, 9M urea, 1mM sodium orthovanadate, 2.5mM sodium pyrophosphate, 1mM β-glycerophosphate). Scrambled shRNA injected muscles from seven mice were pooled together as control and the seven PABPN1 shRNA injected muscles were pooled together for the acetylated peptide pull-down.
Mass spectrometry sample preparation
Peptides were obtained by a tryptic digestion according to the filter-aided sample preparation method as previously described (Wisniewski et al., 2009 ). In brief, 50µg protein was pre-treated with DTT (20mM), IAA (1M) and washed with urea (8M) in between. Protein digestion was carried out with 1.7µg trypsin per muscle at 37ºC overnight. Trypsin was deactivated with 5% formic acid and the peptides were then washed with NaCl (0.5M) and H2O. Subsequently, peptide desalting was performed using C18 Sep-Pack cartridges (Waters), and dried using miVac DUO concentrator (Genevac, UK). Peptides were stored in -20°C. For the acetylome peptides were pulled down using PTMScan Acetyl-Lysine [Ac-K] Immunoaffinity Beads (Cat. #14499; CST, Inc) according to the manufacturer protocol (CST, Inc). In brief, 17mg protein was reduced with DTT (4.5mM) at 55°C for 30 min and then alkylated IAA (100mM) in the dark at room temperature for 15 min. The samples were then diluted 4 times using 20mM HEPES pH 8.0. Protein digestion was carried out with 10ug/ml trypsin at RT overnight. Trypsin was deactivated with trifluoroacetic acid (TFA). Peptides were kept at -80°C and subsequently lyophilized for 48 hours to ensure complete removal of TFA. The peptide pellet was resuspended in Immunoaffinity Purification buffer (IAP) (50mM morpholinepropanesulfonic acid pH 7.2, 10mM sodium phosphate dibasic, 50mM sodium chloride). Resuspended peptides were directly loaded on the immunoaffinity Beads (Cat. #14499; CST, Inc) and were incubated at 4°C for 2 hours. The beads-peptide complexes were washed with 0.15% TFA after IAP and RODI water. The eluted peptides were subsequently purified using C18 tips, and then dried using miVac DUO concentrator from Genevac, UK.
